Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization

Nature Communications

Volumn 6, Issue , 2015, Pages

  Francica, Joseph R ^a   Sheng, Zizhang ^b   Zhang, Zhenhai ^b,c   Nishimura, Yoshiaki ^a   Shingai, Masashi ^a   Ramesh, Akshaya ^d   Keele, Brandon F ^e   Schmidt, Stephen D ^a   Flynn, Barbara J ^a   Darko, Sam ^a   Lynch, Rebecca M ^a   Yamamoto, Takuya ^a   Matus Nicodemos, Rodrigo ^a   Wolinsky, David ^a   Nason, Martha ^a   Valiante, Nicholas M ^f   Malyala, Padma ^f   De Gregorio, Ennio ^f   Barnett, Susan W ^f   Singh, Manmohan ^f   O'Hagan, Derek T ^f   Koup, Richard A ^a   Mascola, John R ^a   Martin, Malcolm A ^a   Kepler, Thomas B ^d   Douek, Daniel C ^a   Shapiro, Lawrence ^b   Seder, Robert A ^a   Barnabas, Betty ^g   Blakesley, Robert ^g   Bouffard, Gerry ^g   Brooks, Shelise ^g   Coleman, Holly ^g   Dekhtyar, Mila ^g   Gregory, Michael ^g   Guan, Xiaobin ^g   Gupta, Jyoti ^g   Han, Joel ^g   Ho, Shi Ling ^g   Legaspi, Richelle ^g   Maduro, Quino ^g   Masiello, Cathy ^g   Maskeri, Baishali ^g   McDowell, Jenny ^g   Montemayor, Casandra ^g   Mullikin, James ^g   Park, Morgan ^g   Riebow, Nancy ^g   Schandler, Karen ^g   Schmidt, Brian ^g   Sison, Christina ^g   Stantripop, Mal ^g   Thomas, James ^g   Thomas, Pamela ^g   Vemulapalli, Meg ^g   Young, Alice ^g   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d BOSTON UNIVERSITY   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^f NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^g NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; VIRUS ENVELOPE PROTEIN; IMMUNOLOGICAL ADJUVANT; MESSENGER RNA; NEUTRALIZING ANTIBODY; VIRUS RNA;

ANTIBODY; ANTIGEN; GENE EXPRESSION; IMMUNIZATION; MUTATION; PROTEIN; VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INNATE IMMUNITY; LONGITUDINAL STUDY; MALE; MEMORY CELL; NEXT GENERATION SEQUENCING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SOMATIC HYPERMUTATION; VIRUS ENVELOPE; VIRUS LOAD; ANIMAL; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LENTIVIRUS INFECTIONS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALIA; PRIMATES;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; BASE SEQUENCE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; IMMUNOGLOBULINS; LENTIVIRUS INFECTIONS; LENTIVIRUSES, PRIMATE; LONGITUDINAL STUDIES; MACACA MULATTA; MOLECULAR SEQUENCE DATA; RNA, MESSENGER; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

EID: 84927155041     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7565     Document Type: Article

References (70)

1. Excler, J. L., Robb, M. L. & Kim, J. H. HIV-1 vaccines: challenges and new perspectives. Hum. Vaccin. Immunother. 10, 1734-1746 (2014).
2. Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199-1204 (2013).
3. Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
4. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
5. Mascola, J. R. & Haynes, B. F. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254, 225-244 (2013).
6. Klein, F. et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153, 126-138 (2013).
7. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
8. Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
9. West, Jr. A. P., Diskin, R., Nussenzweig, M. C. & Bjorkman, P. J. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl Acad. Sci. USA 109, E2083-E2090 (2012).
10. Walker, L. M. et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl Acad. Sci. USA 108, 20125-20129 (2011).
11. Sundling, C. et al. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci. Transl. Med. 4, 142ra196 (2012).
12. Dennison, S. M. et al. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS ONE 6, e27824 (2011).
13. Ketloy, C. et al. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Vet. Immunol. Immunopathol. 125, 18-30 (2008).
14. Gujer, C., Sundling, C., Seder, R. A., Karlsson Hedestam, G. B. & Lore, K. Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation. Immunology 134, 257-269 (2011).
15. Morgan, C. et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 5, e173 (2008).
16. Letvin, N. L. Nonhuman primate models for HIV vaccine development. Immunodefic. Rev. 3, 247-260 (1992).
17. Zhou, T. et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 39, 245-258 (2013).
18. Zhu, J. et al. Somatic populations of PGT135-137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatics. Front. Microbiol. 3, 315 (2012).
19. Zhu, J. et al. De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proc. Natl Acad. Sci. USA 110, E4088-E4097 (2013).
20. Rhesus Macaque Genome, S. et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316, 222-234 (2007).
21. Shingai, M. et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc. Natl Acad. Sci. USA 109, 19769-19774 (2012).
22. Nishimura, Y. et al. Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J. Virol. 84, 4769-4781 (2010).
23. Giudicelli, V. et al. IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucleic Acids Res. 34, D781-D784 (2006).
24. Briney, B. S., Willis, J. R., Hicar, M. D., Thomas, 2nd J. W. & Crowe, Jr. J. E. Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire. Immunology 137, 56-64 (2012).
25. Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55-62 (2014).
26. Pancera, M. et al. Structural basis for diverse N-glycan recognition by HIV-1- neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 20, 804-813 (2013).
27. O'Hagan, D. T., Ott, G. S., De Gregorio, E. & Seubert, A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 30, 4341-4348 (2012).
28. Khurana, S. et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3, 85ra48 (2011).
29. Giannini, S. L. et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24, 5937-5949 (2006).
30. Paillot, R., Grimmett, H., Elton, D. & Daly, J. M. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet. Res. 39, 21 (2008).
31. Lefranc, M. P. et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev. Comp. Immunol. 27, 55-77 (2003).
32. Doria-Rose, N. A. et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84, 1631-1636 (2010).
33. Piantadosi, A. et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83, 10269-10274 (2009).
34. Sather, D. N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769 (2009).
35. Earl, P. L. et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J. Virol. 75, 645-653 (2001).
36. Sundling, C. et al. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J. Exp. Med. 207, 2003-2017 (2010).
37. Kwissa, M., Nakaya, H. I., Oluoch, H. & Pulendran, B. Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119, 2044-2055 (2012).
38. Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492-503 (2010).
39. Boonstra, A. et al. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J. Immunol. 177, 7551-7558 (2006).
40. Pone, E. J. et al. BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NFkappaB pathway. Nat. Commun. 3, 767 (2012).
41. Aranburu, A. et al. TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. J. Immunol. 185, 7293-7301 (2010).
42. Siegrist, C. A. et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23, 615-622 (2004).
43. Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).
44. Malherbe, D. C. et al. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. J. Virol. 88, 12949-12967 (2014).
45. Liao, H. X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476 (2013).
46. Sanz, I. Multiple mechanisms participate in the generation of diversity of human H chain CDR3 regions. J. Immunol. 147, 1720-1729 (1991).
47. Briney, B. S., Willis, J. R. & Crowe, Jr. J. E. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE 7, e36750 (2012).
48. Yin, L. et al. IgM repertoire biodiversity is reduced in HIV-1 infection and systemic lupus erythematosus. Front. Immunol. 4, 373 (2013).
49. Lingwood, D. et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489, 566-570 (2012).
50. Sundling, C. et al. Single-cell and deep sequencing of IgG-switched macaque B cells reveal a diverse Ig repertoire following immunization. J. Immunol. 192, 3637-3644 (2014).
51. Xiao, M., Prabakaran, P., Chen, W., Kessing, B. & Dimitrov, D. S. Deep sequencing and Circos analyses of antibody libraries reveal antigen-driven selection of Ig VH genes during HIV-1 infection. Exp. Mol. Pathol. 95, 357-363 (2013).
52. Breden, F. et al. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS ONE 6, e16857 (2011).
53. Endo, Y. et al. Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus. J. Virol. 74, 6935-6945 (2000).
54. Gautam, R. et al. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J. Virol. 86, 8516-8526 (2012).
55. Lian, Y. et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 79, 13338-13349 (2005).
56. Baudner, B. C. et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26, 1477-1485 (2009).
57. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005).
58. Shu, Y. et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 25, 1398-1408 (2007).
59. Seaman, M. S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439-1452 (2010).
60. Scheid, J. F. et al. A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods 343, 65-67 (2009).
61. Huang, J. et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat. Protoc. 8, 1907-1915 (2013).
62. Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012).
63. Douek, D. C. et al. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J. Immunol. 168, 3099-3104 (2002).
64. Tamura, K. et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28, 2731-2739 (2011).
65. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792-1797 (2004).
66. Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402 (1997).
67. Lefranc, M. P. IMGT, the International ImMunoGeneTics Information System for Immunoinformatics: methods for querying IMGT databases, tools, and web resources in the context of immunoinformatics. Mol. Biotechnol. 40, 101-111 (2008).
68. Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188-1190 (2004).
69. Martin, D. P. et al. RDP3: a flexible and fast computer program for analyzing recombination. Bioinformatics 26, 2462-2463 (2010).
70. Drummond, A. J. & Rambaut, A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol. Biol. 7, 214 (2007).